IN8BIO, INC.
- Dec 30, 2025 · D · $20,119,049 sold of $40,239,043 · 17 investors · min. No minimum reported · role: Executive Officer EDGAR ↗
- Oct 15, 2024 · D · $12,379,983 sold of $12,379,983 · 73 investors · min. No minimum reported · role: Executive Officer EDGAR ↗
- Dec 28, 2023 · D · $14,425,013 sold of $14,425,013 · 20 investors · min. No minimum reported · role: Executive Officer EDGAR ↗
Raised $35M from 73 investors (87% of the $40.2M target) as of the latest filing. Kate is listed as executive officer on 3 filings for this deal.
Sources
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.